Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Photoreceptors and Visual Pathways01:22

Photoreceptors and Visual Pathways

At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category, whereas...
Visual Agnosia01:12

Visual Agnosia

Visual agnosia is a condition characterized by the inability to recognize visually presented objects despite having normal vision. For instance, a person with visual agnosia can describe the shape and color of an object but cannot identify or name it. This impairment does not affect their visual field, acuity, color vision, brightness discrimination, language, or memory. An example of this condition in a social setting is someone at a dinner party asking for "that silver thing with a round end"...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Conversations as a Window Into Cognitive Impairment.

JAMA neurology·2026
Same author

Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio.

JAMA neurology·2026
Same author

Genetic variation in antidiabetic drug targets: associations with Parkinson's disease risk and age at onset.

NPJ Parkinson's disease·2026
Same author

Default mode network failure across the Alzheimer's disease spectrum.

Brain : a journal of neurology·2026
Same author

Genome-wide association study of copy number variations in Parkinson's disease.

NPJ Parkinson's disease·2026
Same author

Progressive rolandic apraxia.

Cortex; a journal devoted to the study of the nervous system and behavior·2026
Same journal

Levodopa responsive childhood-onset generalized dystonia with diaphragmatic involvement associated with an SPTBN2 variant.

Parkinsonism & related disorders·2026
Same journal

Approach to a case of Neuro-Gonadal disorder: Perrault syndrome.

Parkinsonism & related disorders·2026
Same journal

Parakinesia in Chorea: Why attribution of intention is misleading.

Parkinsonism & related disorders·2026
Same journal

Parkinson's disease risk in patients with ocular motor cranial neuropathy: a Korean population-based study.

Parkinsonism & related disorders·2026
Same journal

Target, dose and spacing in network-guided intermittent theta burst stimulation for Parkinson's disease.

Parkinsonism & related disorders·2026
Same journal

Loneliness and mood symptoms in Parkinson's disease: An item-level network analysis.

Parkinsonism & related disorders·2026
See all related articles

Related Experiment Video

Updated: May 23, 2026

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

Attention and visual dysfunction in Parkinson's disease.

Hugo Botha1, Jonathan Carr

  • 1Division of Neurology, Department of Medicine, Faculty of Health Sciences, University of Stellenbosch, PO Box 19063, Tygerberg 7505, Cape Town, South Africa.

Parkinsonism & Related Disorders
|April 17, 2012
PubMed
Summary
This summary is machine-generated.

Visual hallucinations (VH) in Parkinson's disease (PD) are linked to temporal lobe changes and dopamine pathway impairments. These factors also contribute to cognitive decline, affecting attention and working memory.

More Related Videos

Driving Simulation in the Clinic: Testing Visual Exploratory Behavior in Daily Life Activities in Patients with Visual Field Defects
11:12

Driving Simulation in the Clinic: Testing Visual Exploratory Behavior in Daily Life Activities in Patients with Visual Field Defects

Published on: September 18, 2012

A Gaze-Contingent Display Framework for Perceptual Learning Research with Simulated Central Vision Loss
07:12

A Gaze-Contingent Display Framework for Perceptual Learning Research with Simulated Central Vision Loss

Published on: April 11, 2025

Related Experiment Videos

Last Updated: May 23, 2026

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

Driving Simulation in the Clinic: Testing Visual Exploratory Behavior in Daily Life Activities in Patients with Visual Field Defects
11:12

Driving Simulation in the Clinic: Testing Visual Exploratory Behavior in Daily Life Activities in Patients with Visual Field Defects

Published on: September 18, 2012

A Gaze-Contingent Display Framework for Perceptual Learning Research with Simulated Central Vision Loss
07:12

A Gaze-Contingent Display Framework for Perceptual Learning Research with Simulated Central Vision Loss

Published on: April 11, 2025

Area of Science:

  • Neuroscience
  • Cognitive Science
  • Neurology

Background:

  • Visual processing involves complex pathways from the retina to the temporal lobe, influenced by top-down and bottom-up mechanisms.
  • Complex visual hallucinations (VH) are often associated with temporal lobe disorders and impaired monoaminergic pathways.
  • Parkinson's disease (PD) with VH shows characteristic temporal lobe pathology, supported by imaging studies.

Purpose of the Study:

  • To explore the neural underpinnings of visual hallucinations in Parkinson's disease.
  • To investigate the relationship between temporal lobe pathology, monoaminergic pathways, and cognitive deficits in PD with VH.
  • To elucidate the role of dopamine in visual processing, attention, and consciousness in the context of PD.

Main Methods:

  • Review of pathological and imaging findings in Parkinson's disease patients with visual hallucinations.
  • Analysis of the role of monoaminergic pathways, particularly dopamine, in visual processing and cognition.
  • Examination of the functional connectivity between temporal lobe structures, prefrontal cortex, and basal ganglia.

Main Results:

  • Pathological changes in temporal lobes are consistently observed in Parkinson's disease patients experiencing VH.
  • Impairment of ascending monoaminergic pathways is frequently associated with VH in PD.
  • Cognitive decline, including deficits in attention and working memory modulated by dopamine, is a major feature linked to VH.

Conclusions:

  • Temporal lobe integrity and dopaminergic function are critical for normal visual processing and are implicated in VH in Parkinson's disease.
  • Dopamine's role extends to prefrontal cortex function and basal ganglia-mediated gating mechanisms controlling consciousness, relevant to cognitive symptoms in PD.
  • Understanding these neurobiological links is crucial for managing both visual hallucinations and cognitive decline in Parkinson's disease.